Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Gilead loses its head of commercial ops as it takes on daunting sales challenges
Fierce Pharma
Sat, 02/24/18 - 11:21 am
Tags:
Gilead Sciences, restructuring
Treatment Debates Won’t Slow Down Biotechs
Barron's
Fri, 02/23/18 - 09:50 am
Tags:
biotech, Gilead Sciences, CAR-T, Juno Therapeutics, Bellicum
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Xconomy
Fri, 02/23/18 - 07:59 am
Tags:
cell therapy, Gilead Sciences, Sangama, CAR-T, gene editing
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
Thu, 02/22/18 - 11:28 pm
Tags:
migraines, NASH, Amgen, Eli Lilly, Teva Pharmaceutical, Allergan, Gilead Sciences, Novo Nordisk, Intercept Pharma, PBMs
Gilead wins reprieve in Merck's $2.5B patent lawsuit
Biopharma Dive
Thu, 02/22/18 - 09:52 am
Tags:
Gilead Sciences, Merck, patents, Sovaldi, Harvoni, hepatitis C, Idenix
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Thu, 02/22/18 - 09:18 am
Tags:
Gilead Sciences, Biktarvy, Yescarta, selonsertib, filgotinib, Epclusa
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
Tue, 02/20/18 - 09:58 am
Tags:
CAR-T, ICER, Gilead Sciences, Yescarta, Novartis, Kymriah, drug pricing
Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict
Reuters
Sun, 02/18/18 - 10:10 am
Tags:
Gilead Sciences, hepatitis C, patents, Merck, Sovaldi, Harvoni
3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate
Motley Fool
Thu, 02/15/18 - 11:08 am
Tags:
Gilead Sciences, M&A, Editas, Madrigal Pharmaceuticals, CRISPR Therapeutics, Galapagos
Galapagos tries to avoid being acquired by Gilead
GoinPharma
Mon, 02/12/18 - 04:39 pm
Tags:
Galapagos, Gilead Sciences, M&A
Top 10 most productive workforces in biopharma
Fierce Pharma
Mon, 02/12/18 - 11:03 am
Tags:
Pharma, pharma employees, productivity, Gilead Sciences, Celgene, Pfizer, AbbVie, Biogen
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?
Motley Fool
Mon, 02/12/18 - 09:16 am
Tags:
Gilead Sciences, HIV, FDA, Biktarvy
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
Thu, 02/8/18 - 11:18 am
Tags:
GSK, R&D, Pharma CEOs, Emma Walmsley, Advair, Novartis, Sandoz, Gilead Sciences, HIV
A new pill to treat HIV just got approved — and it could shake up a $22 billion market
Business Insider
Thu, 02/8/18 - 09:30 am
Tags:
HIV, Gilead Sciences, FDA, Bictegravir/emtricitabine/tenofovir alafenamide
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short
Fierce Pharma
Thu, 02/8/18 - 09:14 am
Tags:
AbbVie, Mavyret, Gilead Sciences, hepatitis C, Harvoni, Sovaldi
Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins $6B FDA nod
Fierce Pharma
Wed, 02/7/18 - 10:32 pm
Tags:
GSK, Gilead Sciences, HIV, FDA, Biktarvy
Gilead Sciences: Investors Are Betting On A Better 2019
Forbes
Wed, 02/7/18 - 10:20 pm
Tags:
Gilead Sciences, earnings
What to Expect With Gilead Sciences' Q4 Results
Motley Fool
Mon, 02/5/18 - 08:25 am
Tags:
Gilead Sciences, earnings
3 Big Biotech Stocks With Major Catalysts on the Way
Motley Fool
Tue, 01/30/18 - 09:50 am
Tags:
biotech, AbbVie, Neurocrine Biosciences, Elagolix, Celgene, ozanimod, Gilead Sciences, bictegravir
Fast-growing Gilead buys an R&D campus for $135M
Endpoints
Mon, 01/22/18 - 05:39 pm
Tags:
Gilead Sciences, R&D

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.